English  |  正體中文  |  简体中文  |  Items with full text/Total items : 90451/105768 (86%)
Visitors : 11021417      Online Users : 601
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    ASIA unversity > 醫學暨健康學院 > 期刊論文 >  Item 310904400/6722

    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/6722

    Title: Improvement of cardiac function in thalassemia patients using deferiprone
    Authors: Ching-Tien Peng;Chang-Hai Tsai;Kang-His Wu;Chih-Chao Hsu;Tao-Yu Sheng
    Date: 2007-12
    Issue Date: 2009-12-23 14:21:49 (UTC+8)
    Publisher: Asia University
    Abstract: Deferoxamine (DFO) therapy is associated with improved survival of thalassemia patients, and yet cardiac disease remains the main cause of death. Deferiprone (L1) is currently one of the orally active chelating agents used as an alternative to DFO. Both DFO and L1 have demonstrated their ability to normalize cardiac function in patients with iron-induced cardiac disease. Some evidence indicates that L1 is more effective than DFO in cardiac iron removal. Our ability to detect and manage the cardiac complications of thalassemia has also improved dramatically over the last 7 years. Noninvasive
    techniques of quantification of the iron burden using magnetic resonance imaging (MRI) have been validated. Using MRI and echocardiography to monitor cardiac systems, in particular the cardiac functions that are closely associated with iron overload-related complications and mortality, proved to be practical. Our increased understanding of cardiac pathophysiology and our improved ability to detect at-risk populations are yielding improved outcomes and reduced morbidity in these reported patients. The improvement in cardiac function that can be observed during L1 therapy may
    have several mechanisms. Due to its tiny size and physicochemical characteristics, it can readily penetrate iron-loaded myocytes where it may exert anti oxidant activity or bind the excess iron and carry it out of the cell into the circulation where it is excreted, mainly in the urine. In addition, L1’s cardioprotective effects may be related to its ability to mobilize citratebound iron or other forms of nontransferrin-bound iron. We have continued to explore the use of readily available bedside tools, such as echocardiograms and biochemical markers of cardiac dysfunction, to monitor thalassemia
    patients with cardiac complications. Herein, the literature and our own studies/findings are summarized. L1 chelation was found to have marginal benefits in increasing cardiac function and reducing cardiac iron accumulation.
    Relation: Tzu Chi Medical Journal (慈濟醫學雜誌) 19 (4): 192-199
    Appears in Collections:[醫學暨健康學院] 期刊論文

    Files in This Item:

    File SizeFormat

    All items in ASIAIR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback